Pharmaceuticals Analysts Scala & Nedelcovych, along with Dr. Burstein of the Dana-Farber Cancer Institute discuss Novartis’ NATALEE Trial post positive topline results and how will it compare to the Verzenio (LLY) monarchE results on an Analyst/Industry conference call to be held on April 4 at 2 pm. Webcast Link
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Eli Lilly price target raised to $310 from $290 at Jefferies
- Lilly reports Alzheimer’s treatment reduced amyloid in small study, Reuters says
- Viking Therapeutics price target raised to $31 from $20 at BTIG
- ‘Our Best Long-Term Picks’: Morgan Stanley Suggests 3 High-Quality Stocks to Buy Now
- Stifel argues sympathy trading not a predictor for Viking’s pending VK2735 data